Share
Sophie Lamle
LEO Pharma, a global leader in medical dermatology, has appointed Sophie Lamle, D.Phil., as its new Executive Vice President (EVP) of Development.
In her new role, Sophie will join the company’s Global Leadership Team and play a pivotal part in advancing LEO Pharma’s Search & Development model, designed to drive faster, more efficient innovation across its dermatology pipeline.
With more than two decades of experience in the pharmaceutical industry, Sophie brings a strong track record of leading transformative R&D programs. She joins LEO Pharma from Teva Pharmaceuticals, where she headed the global R&D innovative medicines team. During her tenure, she oversaw a diverse portfolio of assets in Immunology and Neuroscience, guiding programs from early discovery all the way through commercialization. Her leadership has consistently focused on advancing science-driven solutions, optimizing clinical development processes, and implementing strategic initiatives that accelerate product delivery.
A native of the United Kingdom, Sophie holds a D.Phil. in Chemistry from the University of Oxford. Her extensive career also includes impactful roles at Vectura, Novartis Pharmaceuticals, and IQVIA, where she contributed to research advancement, operational excellence, and cross-functional development strategies.
Sophie Lamle will formally assume her position as EVP of Development on December 1, 2025. Ahead of her transition, Mark Levick will conclude his service as interim EVP. While stepping down from the interim role, he will continue to support LEO Pharma as a member of the Board of Directors and Chair of the Innovation Committee.
Sophie’s appointment marks a significant step in strengthening the company’s R&D leadership and reinforcing its commitment to delivering breakthrough dermatology solutions worldwide.
